B. Farsaci

发表

Cancer Therapy : Preclinical Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model

Andressa Ardiani, A. Protter, Zhimin Guo, 2013 .

Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model

Andressa Ardiani, A. Protter, Zhimin Guo, 2013, Clinical Cancer Research.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Andressa Ardiani, J. Hodge, S. Gameiro, 2012, Seminars in oncology.

Therapeutic cancer vaccines.

J. Schlom, R. Madan, J. Gulley, 2014, Advances in cancer research.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

K. Savage, D. Neuberg, G. Pinkus, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets

M. Merino, P. Pinto, J. Schlom, 2014, International journal of cancer.

Distinct Effects of Saracatinib on Memory CD8+ T Cell Differentiation

J. Schlom, S. Takai, H. Sabzevari, 2012, The Journal of Immunology.

Vaccine Therapy and Integration with Other Modalities

J. Schlom, P. Kim, J. Gulley, 2013 .

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

F. Guadagni, J. Schlom, A. Spila, 2013, Oncoimmunology.

TGF-β modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression

L. Wakefield, J. Schlom, S. Takai, 2009, Cancer Immunology, Immunotherapy.

Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer

S. Steinberg, J. Schlom, R. Madan, 2013, Cancer Immunology Research.

Q 1 2 Immune Q 2 Impact Induced by PROSTVAC ( PSA-TRICOM ) , Q 3 3 a Therapeutic Vaccine for Prostate Cancer 4 5

S. Steinberg, J. Schlom, R. Madan, 2013 .

Recombinant TRICOM-based Therapeutic Cancer Vaccines

J. Schlom, R. Madan, J. Gulley, 2013 .

Chapter 20 – Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned

J. Schlom, R. Madan, J. Gulley, 2013 .

Design, development and translation of poxvirus-based vaccines for cancer

J. Hodge, A. Kwilas, B. Farsaci, 2011 .

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

J. Higgins, J. Hodge, B. Farsaci, 2012, International journal of cancer.

Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

S. Ferrone, K. Tsang, C. T. Garnett, 2013, International journal of cancer.

Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age.

G. Milone, S. Leotta, B. Farsaci, 2007, Cytotherapy.

Effect of a small molecule BCL‐2 inhibitor on immune function and use with a recombinant vaccine

J. Schlom, S. Takai, H. Sabzevari, 2010, International journal of cancer.

Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines

A. Molinolo, R. Donahue, J. Hodge, 2014, Cancer Immunology Research.

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

R. Donahue, J. Hodge, I. Grenga, 2015, Journal of Immunotherapy for Cancer.

Therapeutic cancer vaccines.

J. Schlom, R. Madan, J. Gulley, 2014, Advances in cancer research.

TWO Therapeutic Cancer Vaccines

J. Schlom, R. Madan, J. Gulley, 2014 .

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy

J. Schlom, P. Kim, J. Gulley, 2014, The Journal of Immunology.

Combination Immunotherapy Lymphocytes: A Rationale for Its Use in Lymphocytes while Preserving Effector T Decreases Human T Regulatory Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax),

J. Schlom, J. Gulley, C. Jochems, 2014 .

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel Alone or in CombinationWith a Therapeutic Cancer Vaccine ( PANVAC ) in PatientsWithMetastatic Breast Cancer A Randomized Clinical Trial

S. Steinberg, N. Ibrahim, J. Murray, 2015 .

CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure

G. Milone, S. Leotta, C. Consoli, 2005, Bone Marrow Transplantation.

Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy

N. Ibrahim, J. Schlom, R. Madan, 2016, Cancer Immunology Research.

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

S. Steinberg, N. Ibrahim, J. Murray, 2015, JAMA oncology.

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL

K. Savage, M. Shipp, K. Kato, 2017 .

A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)

M. Shipp, A. Lesokhin, P. Armand, 2016 .

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

S. Ferrone, K. Tsang, C. T. Garnett, 2013, Journal of Immunotherapy for Cancer.

Abstract 1676: Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

S. Ferrone, K. Tsang, C. T. Garnett, 2013 .

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients

J. Schlom, R. Madan, J. Gulley, 2014, Journal of Immunotherapy for Cancer.

Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study.

K. Savage, M. Shipp, A. Santoro, 2016 .

PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment

J. Schlom, R. Donahue, Lauren M. Lepone, 2014, Journal of Immunotherapy for Cancer.

Therapeutic cancer vaccines.

J. Schlom, R. Madan, J. Gulley, 2014, Advances in cancer research.

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

S. Ferrone, K. Tsang, C. Palena, 2013, Journal of Immunotherapy for Cancer.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Andressa Ardiani, J. Hodge, B. Farsaci, 2012, Seminars in oncology.

Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells

J. Schlom, R. Donahue, I. Grenga, 2013, Journal of Immunotherapy for Cancer.

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 628: Pan-Bcl-2 inhibitor, GX15-070 (Obatoclax), decreases human T regulatory lymphocytes while preserving effector T Lymphocytes: A rationale for its use in combination immunotherapy

J. Schlom, P. Kim, J. Gulley, 2014 .